COMPANY NEWS

Latest News

All the latest news & events from KaNDy Therapeutics.

Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation entitled: ‘ Switching off the heat: A novel, rapidly acting and effective non-hormonal approach to treating hot flashes and other symptoms of the menopause with neurokinin-1,3 receptor antagonism’

Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation entitled: ‘ Switching off the heat: A novel, rapidly acting and effective non-hormonal approach to treating hot flashes and other symptoms of the menopause with [...]

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical Advisor.

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical Advisor. Professor Dhillo will be [...]

KaNDy Therapeutics presents new compelling data with lead candidate NT-814 at The North American Menopause Society 2018 Annual Meeting

~ Treatment with NT-814 resulted in immediate improvements in bothersome post-menopausal symptoms~ ~ Phase Ib/IIa data showed rapid and significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ [...]

KaNDy Therapeutics successfully raises £25 million in a Series C financing. Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018

Stevenage, UK, 29 August 2018 – KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US investor Longitude Capital, and existing [...]

KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls

Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy Therapeutics and NeRRe Therapeutics, its sister [...]

KaNDy Therapeutics announces positive clinical data with lead candidate NT-814 for the treatment of symptoms of the menopause

~Phase Ib/IIa data showed rapid and highly significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ ~NT-814 is being developed to provide a valid alternative to hormone replacement therapy and [...]

KaNDy Therapeutics Managing Director to present at The Anglonordic Life Science Conference

24th May 2018: KaNDy Therapeutics Managing Director, Dr Mary Kerr, is invited to present at The Anglonordic Life Science Conference 11:00am -12.30pm in the Biotech Investment Room, County Hall, London  

Press Release: KaNDy Therapeutics launched to focus on a breakthrough new product in Women’s Health

First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company   Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for [...]

Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt